During the past decade, Regina Elena National Cancer Institute conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 1 clinical trials were completed, i.e. on average, 4.2% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 1 clinical trials were completed. i.e. 12.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Regina Elena National Cancer Institute" #1 sponsor was "Regina Elena Cancer Institute" with 12 trials, followed by "Italian Sarcoma Group" with 5 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials sponsored, "Azienda Unità Sanitaria Locale Reggio Emilia" with 1 trials sponsored and "Deciphera Pharmaceuticals LLC" with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Regina Elena National Cancer Institute" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Alliance for Clinical Trials in Oncology" with 1 trials as a collaborator, "Azienda Sanitaria-Universitaria Integrata di Udine" with 1 trials as a collaborator, "BioNTech SE" with 1 trials as a collaborator and "Breast International Group" with 1 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Regina Elena National Cancer Institute" are "Breast Cancer" (3 trials), "Anesthesiology Management" (2 trials), "Prostate Cancer" (2 trials), "Advanced Chondrosarcoma" (1 trials) and "Advanced Desmoid Tumor" (1 trials). Many other conditions were trialed in "Regina Elena National Cancer Institute" in a lesser frequency.

Most popular intervention types in "Regina Elena National Cancer Institute" are "Drug" (17 trials), "Other" (5 trials), "Biological" (3 trials), "Device" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Cemiplimab" (2 trials), "5-Fluorouracil" (1 trials), "Bevacizumab" (1 trials), "Blood samples and processing" (1 trials) and "Bortezomib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Regina Elena National Cancer Institute" are 21 trials for "All" genders, 7 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Regina Elena National Cancer Institute". undefined are not yet recruiting, 9 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Regina Elena National Cancer Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Regina Elena National Cancer Institute, 6 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 8 trials that are defined as “Not Applicable".